series-a
Stage
1
Investors
About
Arnatar develops RNA-based therapies using its DARGER™ platform to both silence disease-causing genes and upregulate protein expression for cardiometabolic, liver, CNS, and kidney diseases.
Explore Arnatar's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.